MarAprMayJunJulAugSepOct
↩ TodayMon23Mar
Tue24Mar
Wed25Mar
Thu26Mar
Fri27Mar
Sat28Mar
Sun29Mar
Mon30Mar
Tue31Mar
Wed1Apr
Thu2Apr
Fri3Apr
Sat4Apr
Sun5Apr
Mon6Apr
Tue7Apr
Wed8Apr
Fri10Apr
Sat11Apr
Mon13Apr
Tue14Apr
Wed15Apr
Thu16Apr
Fri17Apr
Sat18Apr
Sun19Apr
Mon20Apr
Tue21Apr
Wed22Apr
Thu23Apr
Fri24Apr
Sat25Apr
Sun26Apr
Mon27Apr
Tue28Apr
Wed29Apr
Thu30Apr
Fri1May
Sat2May
Sun3May
Mon4May
Tue5May
Wed6May
Thu7May
Fri8May
Sat9May
Sun10May
Mon11May
Tue12May
Wed13May
Thu14May
Fri15May
Sat16May
Sun17May
Mon18May
Tue19May
Wed20May
Thu21May
Fri22May
Sat23May
Sun24May
Mon25May
Tue26May
Wed27May
Thu28May
Fri29May
Sat30May
Sun31May
Mon1Jun
Tue2Jun
Wed3Jun
Thu4Jun
Fri5Jun
Sat6Jun
Sun7Jun
Mon8Jun
Tue9Jun
Wed10Jun
Thu11Jun
Fri12Jun
Sat13Jun
Sun14Jun
Mon15Jun
Tue16Jun
Wed17Jun
Thu18Jun
Fri19Jun
Sat20Jun
Sun21Jun
Mon22Jun
Wed24Jun
Thu25Jun
Fri26Jun
Sat27Jun
Sun28Jun
Mon29Jun
Wed1Jul
Thu2Jul
Fri3Jul
Sat4Jul
Sun5Jul
Mon6Jul
Tue7Jul
Wed8Jul
Thu9Jul
Fri10Jul
Sat11Jul
Sun12Jul
Mon13Jul
Tue14Jul
Wed15Jul
Thu16Jul
Fri17Jul
Sat18Jul
Sun19Jul
Mon20Jul
Tue21Jul
Wed22Jul
Thu23Jul
Fri24Jul
Sat25Jul
Sun26Jul
Mon27Jul
Tue28Jul
Wed29Jul
Thu30Jul
Fri31Jul
Sat1Aug
Sun2Aug
Mon3Aug
Tue4Aug
Wed5Aug
Thu6Aug
Fri7Aug
Sat8Aug
Sun9Aug
Mon10Aug
Tue11Aug
Wed12Aug
Thu13Aug
Fri14Aug
Sat15Aug
Sun16Aug
Mon17Aug
Tue18Aug
Wed19Aug
Fri21Aug
Sat22Aug
Tue25Aug
Wed26Aug
Thu27Aug
Fri28Aug
Sat29Aug
Sun30Aug
Mon31Aug
Tue1Sep
Wed2Sep
Thu3Sep
Fri4Sep
Sat5Sep
Sun6Sep
Mon7Sep
Tue8Sep
Wed9Sep
Thu10Sep
Fri11Sep
Sat12Sep
Sun13Sep
Mon14Sep
Tue15Sep
Wed16Sep
Thu17Sep
Fri18Sep
Sat19Sep
Sun20Sep
Mon21Sep
Tue22Sep
Wed23Sep
Thu24Sep
Fri25Sep
Sat26Sep
Sun27Sep
Mon28Sep
Tue29Sep
Wed30Sep
Thu1Oct
Fri2Oct
Sat3Oct
51 papers read · 51 surfaced · 9 stood out
Today's lead
Felzartamab plus lenalidomide-dexamethasone versus…
Adding felzartamab to standard treatment significantly extended progression-free survival in patients with relapsed or refractory multiple myeloma.
Haiyan He, Jingjing Shang, Yafei Wang et al. · The Lancet. Haematology
10/10
Impact score
Time to impact (est.)
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Standard addition
Complete Response Durability After TAR-200 and Nadofaragene…
TAR-200 and nadofaragene firadenovec achieved sustained complete responses in bladder cancer patients who had failed prior BCG therapy.
Underserved or high-risk populationsDiagnostic accuracy of a DenseNet-121 deep learning algorithm for…
A deep learning algorithm screened chest radiographs with 99.7% accuracy in ruling out abnormalities, potentially reducing unnecessary follow-up testing.
Standard additionToripalimab consolidation after chemoradiotherapy in limited-stage…
Consolidative immunotherapy after standard treatment showed improved survival signals in early-stage small cell lung cancer with manageable side effects.
Standard additionArtificial intelligence for rapid on-site evaluation of lymph node…
AI-enhanced rapid analysis of lymph node biopsies improved diagnostic accuracy compared to traditional microscopy methods.